



IFW

Docket: 28575/US/US


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh	
Application No.:	10/631,029	
Filing Date:	July 29, 2003	Examiner: Unknown
Title:	Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidendiamine Compounds	Group Art Unit:

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97(B)

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this document is being sent via First Class U.S. mail addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 25 day of August, 2004.

  
Barbara A. Avery


Dear Sir:


Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (2 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Respectfully submitted,

DORSEY & WHITNEY LLP  
Customer Number 25763

Date: August 25, 2004

By:   
Scott D. Rothenberger, Reg. No.  
41,277  
Intellectual Property Department  
Suite 1500  
50 South Sixth Street  
Minneapolis, MN 55402-1498  
(612) 340-8819



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/631,029
				Filing Date	July 29, 2003
				First Named Inventor	Rajinder Singh
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket Number	28575/US/US

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number – Kind Code (if known)				YES	NO
		WO	00/59893	10/12/2000	Krenitsky Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
		"Synthesis and Antiinflammatory Properties of O-Carboxyphenylamino Pyrimidines", Kiev Scientific-Research Institute of Pharmacology and Toxicology, translated from Khimko-framatsevticheskii Zhurnal, Vol. 17, No. 11, pp. 1304-1307, November 1983, 1984 Plenum Publishing Corporation, pgs. 777-779, original article submitted January 12, 1983.	<input type="checkbox"/>	<input type="checkbox"/>
		"Chemistry of Heterocyclic Compounds, Vol. 2, No. 5, September –October 1966, The Faraday Press, Inc., pp. 606-611	<input type="checkbox"/>	<input type="checkbox"/>
		"SU Alcune 5-Fluoro-6-Anilino-Amminopirimidine", M.G. Biressi, G. Cantarelli, M. Carissimi, F. Ravenna, Bolletino Chimico Farmaceutico, 1966, Vol. 105, No. 9, pp. 660-665	<input type="checkbox"/>	<input type="checkbox"/>
		"Synthesis of 2,4-Disubstituted 5-Aminopyrimidine-6- Carboxylic Acids Derivatives Part I.", Polish Journal of Pharmacology and Pharmacy, Vol. 28, No. 1, 1976, pp. 61-67	<input type="checkbox"/>	<input type="checkbox"/>
		"Synthesis and Hypolipidemic Activity of 6-Alkyl (Aryl)Amino-2-Chloropyrimidine-4-Carboxylic Acid Esters", Chemija Chemistry, 1998, ISSN 0235-7216, pp. 90-92	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number		10/631,029	
				Filing Date		July 29, 2003	
				First Named Inventor		Rajinder Singh	
				Art Unit		Unknown	
				Examiner Name		Unknown	
Sheet	2	of	2	Attorney Docket Number		28575/US/US	
<b>OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS</b>							
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					TRANSLATION
		<b>“Chemotherapy for Onchocerciasssis: Results of <i>in vitro</i> Experiments with Promising New Compounds”, Tropical Medicine and International Health, Vol. 3, No. 5, pp. 397-407, May 1998, 1998 Blackwell Science Ltd.</b>					<input type="checkbox"/> <input type="checkbox"/>
		<b>“Khimiko-Farmatsevtsevtichesskii Zhurnal”, 1983, Vol 11, pp. 1281-1282, 1304-1307</b>					<input type="checkbox"/> <input type="checkbox"/>
EXAMINER SIGNATURE				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							